# OnCo record her2-positive-breast-brain-metastases (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/her2-positive-breast-brain-metastases/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "her2-positive-breast-brain-metastases" ;
  schema:name "HER2-positive breast cancer with brain metastases"@en ;
  schema:alternateName "HER2-positive brain metastases"@en, "Central nervous system metastases from HER2-positive breast cancer"@en, "Intracranial HER2-positive disease"@en ;
  schema:description "The brain is the weak point of HER2-positive breast cancer: antibodies control the rest of the body but cross poorly into the brain, so up to half of patients with advanced disease develop brain metastases. Tucatinib with trastuzumab and capecitabine was the first drug proven to help, and trastuzumab deruxtecan shrinks brain lesions in most patients."@en ;
  schema:url <https://onco.cc/cancers/her2-positive-breast-brain-metastases/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Brain_metastasis> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1914609>, <https://doi.org/10.1200/JCO.20.00775>, <https://www.nature.com/articles/s41591-024-03261-7> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/secondary-brain-tumours/>, <https://onco.cc/terms/her2-brain-metastases/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/pairings/tucatinib-triplet-brain-mets/>, <https://onco.cc/terms/leptomeningeal-disease/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-brain-delivery/> ;
  onco:pipeline <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/trials/her2climb-05/>, <https://onco.cc/ideas/idea-cns-first-adc-strategy/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/trastuzumab-rezetecan/>, <https://onco.cc/drugs/pyrotinib/>, <https://onco.cc/technologies/her2-pet/> ;
  onco:standardOfCare <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/terms/stereotactic-radiosurgery/>, <https://onco.cc/trials/alliance-n0574/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/trials/her2climb/>, <https://onco.cc/terms/her2-brain-metastases/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-breast12/>, <https://onco.cc/trials/destiny-breast03/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/trials/her2climb-05/>, <https://onco.cc/drugs/neratinib/>, <https://onco.cc/drugs/lapatinib/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/trials/her2climb-02/> .